美国BG Medicine, Inc.
BG Medicine是一家致力于发现、开发和商品化以生物标志物为基础的新型分子诊断技术，并借此来改善患者治疗结果和控制医疗费用的生命科学公司。该公司宣布，在D轮融资中获得总额为4000万美元的资金。此轮融资包括新投资者Legg Mason Capital Management、GE Asset Management、SMALLCAP World Fund和现有投资者Flagship Ventures、Gilde Healthcare Partners、Humana、Stelios Papadopoulos。该笔资金将用于推动公司现有的两个诊断产品的研发和商业化，并将支持公司继续进行其他产品的研发。




BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. Our technology platform uniquely positions us to rapidly and cost-effectively discover new high-value biomarkers over a broad range of therapeutic categories that promise to be highly correlated to clinical outcomes. We have built a broad product pipeline that focuses on cardiovascular disease, cancer and CNS disorders through academic collaborations and initiatives with major pharmaceutical companies, the U.S Food and Drug Administration, or FDA and other healthcare organizations.

We discover biomarkers employing our proprietary, versatile, scalable technology platform that enables us to identify new biomarkers by integrating, and automating measurement, analysis, characterizations and interpretations of proteins and small non-protein biological molecules, or metabolites, collected from bodily fluids.

Through our biomarker discovery and product development programs we develop molecular diagnostic tests that are intended to provide information to physicians that will greatly improve patient treatment decisions. Our tests are designed to predict a patient’s response to drug therapy, determine the potential toxicity of therapeutic agents to patients, identify patients who have or are likely to develop a specific disease, predict a patient’s prognosis once a disease has been diagnosed and monitor a patient’s disease progression or drug response.